{"id":393048,"date":"2020-12-03T14:33:31","date_gmt":"2020-12-03T19:33:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=393048"},"modified":"2020-12-03T14:33:31","modified_gmt":"2020-12-03T19:33:31","slug":"veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/","title":{"rendered":"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020<\/b><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=52342712&amp;newsitemid=20201203005959&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc.&amp;index=1&amp;md5=d28fb9a052d424a5d1997c94624a35bf\">Veracyte, Inc.<\/a> (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&amp;D Day for investors and analysts on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST.\n<\/p>\n<p>\nThe event will feature Veracyte senior management who will provide an overview of the company\u2019s vision for transforming patient care in lung cancer, as well as leading pulmonologists who will discuss the challenges and opportunities in lung cancer diagnosis and treatment. Veracyte will also provide updates on its lung cancer product pipeline, including its Nasal Swab Test, for early diagnosis of lung cancer, and Percepta Atlas, for informing treatment decisions at the time of diagnosis. The company plans to launch both products in the second half of 2021.\n<\/p>\n<p>\nA link to register for the event is available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fonlinexperiences.com%2Fscripts%2FServer.nxp%3FLASCmd%3DAI%3A4%3BF%3AQS%2110100%26ShowUUID%3DEBA7324B-C639-4F9F-A1C2-37BD251B2534&amp;esheet=52342712&amp;newsitemid=20201203005959&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=61f100f782320726ab3357a2b0118185\">here<\/a> and can also be accessed through Veracyte\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.veracyte.com%2Fevents-presentations&amp;esheet=52342712&amp;newsitemid=20201203005959&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.veracyte.com%2Fevents-presentations&amp;index=3&amp;md5=b1c65d0a3b8bbadce20954d56f5e22f9\">https:\/\/investor.veracyte.com\/events-presentations<\/a>. A replay of the presentation will be available on the company\u2019s website for approximately 90 days.\n<\/p>\n<p><b>About Veracyte<\/b><\/p>\n<p>\nVeracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company\u2019s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company\u2019s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte\u2019s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com&amp;esheet=52342712&amp;newsitemid=20201203005959&amp;lan=en-US&amp;anchor=www.veracyte.com&amp;index=4&amp;md5=fac67aa56a5cced34b0d39b262fc728d\">www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201203005959\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201203005959\/en\/<\/a><\/span><\/p>\n<p><b>Investors and Media Contact:<br \/>\n<\/b><br \/>Tracy Morris<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:tracy.morris@veracyte.com\">tracy.morris@veracyte.com<br \/>\n<\/a><br \/>650-380-4413\n<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Medical Devices Health Genetics Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201203005959\/en\/791654\/3\/Veracyte_RGB_LRG_H_registered.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&amp;D Day for investors and analysts on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST. The event will feature Veracyte senior management who will provide an overview of the company\u2019s vision for transforming patient care in lung cancer, as well as leading pulmonologists who will discuss the challenges and opportunities in lung cancer diagnosis and treatment. Veracyte will also provide updates on its lung cancer product pipeline, including its Nasal Swab Test, for early diagnosis of lung cancer, and Percepta Atlas, for informing treatment decisions at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-393048","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&amp;D Day for investors and analysts on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST. The event will feature Veracyte senior management who will provide an overview of the company\u2019s vision for transforming patient care in lung cancer, as well as leading pulmonologists who will discuss the challenges and opportunities in lung cancer diagnosis and treatment. Veracyte will also provide updates on its lung cancer product pipeline, including its Nasal Swab Test, for early diagnosis of lung cancer, and Percepta Atlas, for informing treatment decisions at &hellip; Continue reading &quot;Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T19:33:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020\",\"datePublished\":\"2020-12-03T19:33:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/\"},\"wordCount\":370,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/\",\"name\":\"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-03T19:33:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 - Market Newsdesk","og_description":"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&amp;D Day for investors and analysts on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST. The event will feature Veracyte senior management who will provide an overview of the company\u2019s vision for transforming patient care in lung cancer, as well as leading pulmonologists who will discuss the challenges and opportunities in lung cancer diagnosis and treatment. Veracyte will also provide updates on its lung cancer product pipeline, including its Nasal Swab Test, for early diagnosis of lung cancer, and Percepta Atlas, for informing treatment decisions at &hellip; Continue reading \"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T19:33:31+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020","datePublished":"2020-12-03T19:33:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/"},"wordCount":370,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/","name":"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-03T19:33:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-to-host-virtual-lung-cancer-rd-day-on-wednesday-december-16-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte to Host Virtual Lung Cancer R&amp;D Day on Wednesday, December 16, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=393048"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393048\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=393048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=393048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=393048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}